Influence Of The Intensity Of The Conditioning Regimens On The Risks Of Gvhd In Patients Receiving Rituximab Prophylaxis During Allogeneic Stem Cell Transplantation (Allosct)
BLOOD(2018)
Abstract
Purpose: Rituximab (R) use can attenuate the risks of graft-versus-host disease (GVHD) after non-myeloablative allogeneic (NMA) alloSCT. There is a paucity of information on the impact of this strategy in patients receiving myeloablative (MA) conditioning.
MoreTranslated text
Key words
allogeneic stem cell transplantation,rituximab prophylaxis,gvhd
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined